Hip conditions treated with Stem Cell Therapy and PRP
In this video, Ross Hauser, MD discusses some of the most common hip conditions that we treat at Caring Medical with Stem Cell Therapy and Platelet Rich Plas...
By: Caring Medical and Rehabilitation Services
Originally posted here:
Hip conditions treated with Stem Cell Therapy and PRP - Video
PUBLIC RELEASE DATE:
20-Mar-2014
Contact: Anne DeLotto Baier abaier@health.usf.edu 813-974-3303 University of South Florida (USF Innovation)
Tampa, FL (Mar. 20, 2014) Traumatic brain injuries (TBI), sustained by close to 2 million Americans annually, including military personnel, are debilitating and devastating for patients and their families. Regardless of severity, those with TBI can suffer a range of motor, behavioral, intellectual and cognitive disabilities over the short or long term. Sadly, clinical treatments for TBI are few and largely ineffective.
In an effort to find an effective therapy, neuroscientists at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery in the USF Health Morsani College of Medicine, University of South Florida, have conducted several preclinical studies aimed at finding combination therapies to improve TBI outcomes.
In their study of several different therapiesalone and in combinationapplied to laboratory rats modeled with TBI, USF researchers found that a combination of human umbilical cord blood cells (hUBCs) and granulocyte colony stimulating factor (G-CSF), a growth factor, was more therapeutic than either administered alone, or each with saline, or saline alone.
The study appeared in a recent issue of PLoS ONE.
"Chronic TBI is typically associated with major secondary molecular injuries, including chronic neuroinflammation, which not only contribute to the death of neuronal cells in the central nervous system, but also impede any natural repair mechanism," said study lead author Cesar V. Borlongan, PhD, professor of neurosurgery and director of USF's Center of Excellence for Aging and Brain Repair. "In our study, we used hUBCs and G-CSF alone and in combination. In previous studies, hUBCs have been shown to suppress inflammation, and G-CSF is currently being investigated as a potential therapeutic agent for patients with stroke or Alzheimer's disease."
Their stand-alone effects have a therapeutic potential for TBI, based on results from previous studies. For example, G-CSF has shown an ability to mobilize stem cells from bone marrow and then infiltrate injured tissues, promoting self-repair of neural cells, while hUBCs have been shown to suppress inflammation and promote cell growth.
The involvement of the immune system in the central nervous system to either stimulate repair or enhance molecular damage has been recognized as key to the progression of many neurological disorders, including TBI, as well as in neurodegenerative diseases such as Parkinson's disease, multiple sclerosis and some autoimmune diseases, the researchers report. Increased expression of MHCII positive cellscell members that secrete a family of molecules mediating interactions between the immune system's white blood cellshas been directly linked to neurodegeneration and cognitive decline in TBI.
View post:
USF study finds stem cell combination therapy improves traumatic brain injury outcomes
The DIY finger-prick technique opens door for extensive stem cell banking
1. Scientists at A*STARs Institute of Molecular and Cell Biology (IMCB) have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood. The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing. The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.
3. Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the worlds first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.
4. The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.
5. By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.
6. Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested ifdonors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests.
Read the original here:
:: 20, Mar 2014 :: A*STAR SCIENTISTS CREATE STEM CELLS FROM A DROP OF BLOOD
Freeport, Bahamas (PRWEB) March 18, 2014
Okyanos Heart Institute, whose mission it is to bring a new standard of care and a better quality of life to patients with coronary artery disease (CAD) using adult stem cell therapy, announced today it has raised $8.9 million in its Series B offering. Passion Group founder Ali Shawkat led the round and is a visionary entrepreneur-investor with success in a diverse set of industries including cellular services, telecom, media and healthcare.
Okyanos has the vision, medical leadership, adult stem cell technology and business model to better the lives of millions of patients, their families and society, said Shawkat. Cell therapy promises to be a new pillar of medicine as it is based on the natural biology of the body.
"This funding brings Okyanos' total funding to $14.2 million. Financial strength is integral to our commitment to treat patients with cardiac cell therapy at the highest standards of safety and care, stated Matthew Feshbach, co-founder and CEO of Okyanos.
Okyanos' cardiac cell therapy utilizes cells known as adipose-derived stem and regenerative cells (ADRCs), processed by Cytori Therapeutics (NASDAQ: CYTX) Celution system, a technology which has been approved and is commercially available in Europe, Australia, New Zealand, Singapore and other international jurisdictions for various indications of use.
The company has procured a state-of-the-art Philips cath lab and is building out a center of excellence capable of treating over 1000 patients per year in Freeport, The Bahamas. Based on the recommendations of the Bahamas Stem Cell Task Force, which thoroughly studied the safety and efficacy of adult stem cell therapy, the Bahamas passed stem cell legislation in August, 2013.
Feshbach further stated, We have a sophisticated, entrepreneurial group of investors who are like-minded in our purpose to safely improve the quality of life of patients suffering from illnesses such as CAD, using adult stem cells derived from adipose (fat) tissue, added Feshbach. We appreciate the significant leadership and support of Mr. Shawkat who shares the Okyanos commitment.
The company will begin treating patients with coronary artery disease using their own stem cells in the summer of 2014.
About Okyanos Heart Institute: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of rivers, symbolizes restoration of blood flow. For more information, go to http://www.okyanos.com.
Go here to see the original:
Okyanos Heart Institute Announces Completion of Investment Funding
By genetic reprogramming, matured human cells, usually blood cells, can be transformed into hiPSCs. As hiPSCs exhibit properties remarkably similar to human embryonic stem cells, they are invaluable resources for basic research, drug discovery and cell therapy. In countries like Japan, USA and UK[1], a number of hiPSC bank initiatives have sprung up to make hiPSCs available for stem cell research and medical studies.
Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the world's first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.
The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.
By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.
Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, "It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested if donors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests."
Dr Stuart Alexander Cook, Senior Consultant at the National Heart Centre Singapore and co-author of the paper, said "We were able to differentiate the hiPSCs reprogrammed from Jonathan's finger-prick technique, into functional heart cells. This is a well-designed, applicable technique that can unlock unrealized potential of biobanks around the world for hiPSC studies at a scale that was previously not possible."
Prof Hong Wanjin, Executive Director at IMCB, said "Research on hiPSCs is now highly sought-after, given its potential to be used as a model for studying human diseases and for regenerative medicine. Translational research and technology innovations are constantly encouraged at IMCB and this new technique is very timely. We hope to eventually help the scientific community gain greater accessibility to hiPSCs for stem cell research through this innovation."
[1] New York Stem Cell Foundation, California Institute for Regenerative Medicine, Wellcome Trust Sanger Institute and Kyoto University Center for iPS Cell Research & Application are some institutes which are establishing hiPSC banks.
The research findings described in this media release can be found in the Stem Cell Translational Medicine Journal, under the title, "Human Finger-prick iPSCs Facilitate the Development of Stem Cell Banking" by Hong-Kee Tan,1, Cheng-Xu Delon Toh,1,16, Dongrui Ma,2,16, Binxia Yang,1, Tong Ming Liu,3, Jun Lu,2, Chee-Wai Wong,1, Tze-Kai Tan,1, Hu Li,4, Christopher Syn,5,15, Eng-Lee Tan,6,7, Bing Lim,3,8, Yoon-Pin Lim,9,10,11, Stuart A. Cook,2,12,13,14, Yuin-Han Loh,1,15.
1. Epigenetics and Cell Fates Laboratory, A*STAR Institute of Molecular and Cell Biology, 61 Biopolis Drive Proteos, Singapore 138673, Singapore 2. Research and Development Unit (RDU), National Heart Centre Singapore, Singapore 3. Stem Cell and Developmental Biology, Genome Institute of Singapore, A*STAR, Singapore 4. Center for Individualized Medicine, Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, USA 5. Health Sciences Authority, Singapore 6. Centre for Biomedical and Life Sciences, Singapore Polytechnic, Singapore 7. Department of Paediatrics, University Children's Medical Institute, National University Hospital, Singapore 8. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA 9. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 10. NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore 11. Bioinformatics Institute, A*STAR, Singapore 12. Duke-NUS Graduate Medical School, Singapore 13. Royal Brompton Hospital, London, UK 14. National Heart & Lung Institute, Imperial College, London, UK 15. Department of Biological Sciences, National University of Singapore, Singapore
See more here:
A*STAR Scientists Create Stem Cells From a Drop of Blood
Stem cell therapy -- beyond the headlines: Timothy Henry at TEDxGrandForks
There is considerable excitement about the use of stem cells for cardiovascular disease. Stem cells are unspecialized cells with the unique property to self-...
By: TEDx Talks
See the rest here:
Stem cell therapy -- beyond the headlines: Timothy Henry at TEDxGrandForks - Video
HONG KONG--(BUSINESS WIRE)--Hong Kongs renowned 159 Regenerative Medicine Group, a group of life science experts specializing in aging and anti-aging and regenerative medicine, today announces its Hong Kong Tour for Rebirth, a week long trip to Hong Kong that will extend, protect and enhance the lives of those who take part.
Bringing the Groups Nobel Prize-based iPS stem cell technology and its superior medical beauty and anti-aging healthcare services together with the beauty of Hong Kong the Pearl of the Orient the tour will offer participants a once-in-a-lifetime chance to enjoy an entirely new way of living. This incredible experience involves a course of Autologous Hematopoietic Stem Cell transplantation, followed by exposure to Hong Kongs world-class landmarks and multinational cuisines.
Beginning with an introduction to the Groups services at its state-of-the-art Anti-Aging Centre and with the participants health at the focus of every one of the seven days, the tour will be a professional and personalized anti-aging service, which will not only enhance the participants quality of life, but also prolong their lifespans.
Highlights of the tour include:
The total value of this unique tour is HK $600,000. For a limited time, the tour is available at the preferential price of HK $390,000.
About the Group
159 Regenerative Medicine Group, a subsidiary of Hong Kong Life Sciences and Technologies Group Limited (Stock Code: 8085), has been developing and perfecting stem cell treatment methods for 15 years. Based on the Nobel Prize-based iPS stem cell technology, in 2012 the Group developed a series of Autologous Hematopoietic Stem Cell production, anti-aging and medical treatments, providing a one-stop service which protects, produces and preserves stem cells. The Group also offers professional medical consultation, GMP laboratory testing, application Autologous Hematopoietic Stem Cell technology, and several unique 360-degree human aging detection techniques to assess the aging process.
Hotline: 852-3588-0900
Read this article:
159 Regenerative Medicine Group Launches Hong Kong Tour for Rebirth
PRC: Stem cell group submitted fake SEC registration. At a press conference in Manila on Monday, March 17, Professional Regulation Commission chairperson Teresita Manzala said the PRC endorsement documents allegedly submitted by the Philippine Society for Stem Cell Medicine (PSSCM) to the Securities and Exchange Commission (SEC) were fabricated and have her tampered signature. The SEC previously revoked the corporate registration of the PSSCM. Danny Pata
In a statement, Professional Regulation Commission (PRC) chair Teresita Manzala said she has asked the Professional Regulatory Board of Medicine (PRBOM) to initiate, investigate and file charges against doctors Leo Olarte, Bu Castro, Rey Melchor Santos, Oscar Tinio and Jose Asa Sabili before the PRCs legal division.
Olarte is the current president of the PMA.
The five doctors are all incorporators of the Philippine Society for Stem Cell Medicine (PSSCM,) which was able to obtain an SEC certificate despite previously being denied corporate registration. They were able to do this, said the statement, by submitting false PRC endorsements to the commission.
The PRBOM eventually got hold of a copy of the SEC Registration. On examination of the supposed PRC Endorsement, it was noted that the reference regulatory law used was the Philippine Veterinary Law of 2004, instead of Republic Act 2382, otherwise known as the Medical Act of 1959, and there appeared a signature of the PRC Chairperson, the PRC statement said.
Manzala said complaints were filed against the doctors for unprofessional, dishonorable and unethical conduct.
According to the statement, the incorporators later denied participation in obtaining the SEC registration, instead naming a Dr. Mike Aragon as the person who obtained the certification.
In a notarized affidavit submitted to the PRBOM, 'Dr. Mike Aragon' declared that he was the person authorized to register a corporation to be called 'Philippine Society for Stem Cell Medicine' and admitted paying 15,000 pesos to a trading company for them to file the necessary documents for incorporation of the PSSCM, the PRC statement said.
But Aragon claimed to have had no participation whatsoever in the actual processing of the SEC papers for incorporating the PSSCM. Patricia Denise Chiu/BM, GMA News
See the original post here:
5 doctors charged with falsifying papers to get certificate for stem cell group
FRESNO, Calif. (KFSN) -- Umbilical cord stem cell banking can be expensive and controversial, but Jamie and Ben Page decided to bank their daughter Harlow's stem cells, just in case. Then, "just in case" became a reality.
She spins, kicks, and giggles. Like most five year olds, Harlow Page is full of energy.
"This is Harlow when she was first born. We had heard about cord blood banking and talked about it a lot and thought let's just go for it and have it just as a backup," said Jamie Page, Harlow's mom.
It turns out they did need it. Harlow had cancer in her uterus.
"On the ultrasound they immediately saw that there was a mass in her abdomen about the size of a grapefruit," Jamie said.
After a year of chemo, the tumor was gone. Doctors wanted to keep it that way.
"So, when the doctors found out we actually had her own stem cells they were very excited," Jamie said.
"I think that her umbilical cord cells were used as a boost to her own cells when we harvested her to have adequate cells for reconstitution," said Elaine Morgan, MD, Oncologist, Lurie Children's Memorial Hospital.
Dr. Morgan does not advocate private cord stem cell banking at birth to be saved for a healthy baby's later use, because it's not clinically useful and it's expensive.
The Pages paid almost $2,000 for the initial banking fee, plus an extra $125 per year.
By Amber South
asouth@publicopinionnews.com @AESouthPO on Twitter
MERCERSBURG >> Two years after a stem cell transplant, Chevy Hockenberry is growing in mind and body toward the 4-year-old that he is.
He has started a preschool program, and is improving his speech and getting physically stronger.
"He's just very much like a normal boy now," said his mom, Melissa Johnson, of Mercersburg. He is the son of Lance Hockenberry, Fayetteville.
But Chevy continues to wear hearing aids and glasses, and still has some physical issues with his bones to contend with as he continues his journey living with Hurlers syndrome.
Public Opinion last talked to Johnson in March 2012, about a week before the stem cell transplant surgery to prevent the disease from gaining more ground inside Chevy's little body.
Doctors diagnosed Chevy with Hurlers syndrome in January 2012. The rare, inherited disease prevents the body from producing an enzyme that helps break down and process long chains of sugar molecules, according to the University of Maryland Medical Center's website. Without the enzyme, the sugar molecules can build up and damage organs.
Chevy stayed at Milton S. Hershey Medical Center for six months after his surgery. The results of the surgery were not immediately great.
"He got really sick after the transplant," Johnson said.
See the original post:
Stem cell transplant helps boy grow past rare disease